{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:10:07Z","timestamp":1784765407760,"version":"3.55.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T00:00:00Z","timestamp":1748822400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.jtct.2025.05.023","type":"journal-article","created":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T19:47:05Z","timestamp":1748893625000},"page":"693.e1-693.e9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Pilot Study of Low-Dose Splenic Irradiation and Transplantation in JAK Inhibitor-Refractory Myelofibrosis With Splenomegaly"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-9531-0065","authenticated-orcid":false,"given":"Kristin","family":"Rathje","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nico","family":"Gagelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artur","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3568-0710","authenticated-orcid":false,"given":"Johanna","family":"Richter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Rautenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherina","family":"Lueck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Wolschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans Christian","family":"Reinhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Ayuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Schroeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5103-9966","authenticated-orcid":false,"given":"Nicolaus","family":"Kr\u00f6ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jtct.2025.05.023_bib0001","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s11899-020-00598-x","article-title":"Non-pharmacologic management of splenomegaly for patients with myelofibrosis: is there any role for splenectomy or splenic radiation in 2020?","volume":"15","author":"Sankar","year":"2020","journal-title":"Curr Hematol Malig Rep"},{"issue":"7","key":"10.1016\/j.jtct.2025.05.023_bib0002","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1007\/s00277-020-04069-4","article-title":"Modern management of splenomegaly in patients with myelofibrosis","volume":"99","author":"Tremblay","year":"2020","journal-title":"Ann Hematol"},{"issue":"2","key":"10.1016\/j.jtct.2025.05.023_bib0003","first-page":"188","article-title":"Portal hypertension complicating myelofibrosis in a patient without portal or hepatic vein thrombosis","volume":"27","author":"Qi","year":"2014","journal-title":"Ann Gastroenterol"},{"issue":"28","key":"10.1016\/j.jtct.2025.05.023_bib0004","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.3748\/wjg.v18.i28.3770","article-title":"Multiple esophageal variceal ruptures with massive ascites due to myelofibrosis-induced portal hypertension","volume":"18","author":"Tokai","year":"2012","journal-title":"World J Gastroenterol"},{"issue":"6","key":"10.1016\/j.jtct.2025.05.023_bib0005","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/j.amjmed.2009.12.031","article-title":"The underdiagnosis of pulmonary hypertension in myelofibrosis","volume":"123","author":"Thachil","year":"2010","journal-title":"Am J Med"},{"issue":"9","key":"10.1016\/j.jtct.2025.05.023_bib0006","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jtct.2025.05.023_bib0007","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1001\/jamaoncol.2017.5818","article-title":"Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: a randomized clinical trial","volume":"4","author":"Mascarenhas","year":"2018","journal-title":"JAMA Oncol"},{"issue":"9","key":"10.1016\/j.jtct.2025.05.023_bib0008","doi-asserted-by":"crossref","first-page":"e735","DOI":"10.1016\/S2352-3026(23)00174-6","article-title":"Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 study","volume":"10","author":"Gerds","year":"2023","journal-title":"Lancet Haematol"},{"issue":"7","key":"10.1016\/j.jtct.2025.05.023_bib0009","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/s41409-023-01968-8","article-title":"Spleen volume and length determined by computed tomography impact outcome after allogeneic stem cell transplantation for myelofibrosis","volume":"58","author":"Luther","year":"2023","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jtct.2025.05.023_bib0010","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1016\/S2352-3026(22)00330-1","article-title":"Splenomegaly in patients with primary or secondary myelofibrosis who are candidates for allogeneic hematopoietic cell transplantation: a Position Paper on behalf of the Chronic Malignancies Working Party of the EBMT","volume":"10","author":"Polverelli","year":"2023","journal-title":"Lancet Haematol"},{"issue":"20","key":"10.1016\/j.jtct.2025.05.023_bib0011","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1182\/blood.2023021218","article-title":"How I treat transplant-eligible patients with myelofibrosis","volume":"142","author":"Kr\u00f6ger","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jtct.2025.05.023_bib0012","doi-asserted-by":"crossref","first-page":"e62","DOI":"10.1016\/S2352-3026(23)00305-8","article-title":"Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT\/ELN International Working Group","volume":"11","author":"Kroger","year":"2024","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1016\/j.jtct.2025.05.023_bib0013","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41409-024-02437-6","article-title":"Navigating \u2018grey areas\u2019 and challenges during evaluation of transplant eligibility in specific myelofibrosis populations: a perspective on behalf of the Chronic Malignancies Working Party of the EBMT","volume":"60","author":"Polverelli","year":"2025","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.jtct.2025.05.023_bib0014","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1002\/ajh.27252","article-title":"Splenic irradiation for myelofibrosis prior to hematopoietic cell transplantation: a global collaborative analysis","volume":"99","author":"Gagelmann","year":"2024","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.jtct.2025.05.023_bib0015","article-title":"Splenic irradiation prior to allogeneic transplant conditioning in myelofibrosis: a pilot experience","volume":"71","author":"Campodonico","year":"2023","journal-title":"Curr Res Transl Med"},{"issue":"2","key":"10.1016\/j.jtct.2025.05.023_bib0016","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1046\/j.1365-2141.1998.00998.x","article-title":"Splenic irradiation for symptomatic splenomegaly associated with myelofibrosis with myeloid metaplasia","volume":"103","author":"Elliott","year":"1998","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.jtct.2025.05.023_bib0017","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s12185-016-1940-3","article-title":"Splenic irradiation provides transient palliation for symptomatic splenomegaly associated with primary myelofibrosis: a report on 14 patients","volume":"103","author":"Kitanaka","year":"2016","journal-title":"Int J Hematol"},{"issue":"12","key":"10.1016\/j.jtct.2025.05.023_bib0018","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1080\/10428194.2017.1321747","article-title":"Low-dose splenic irradiation prior to hematopoietic cell transplantation in hypersplenic patients with myelofibrosis","volume":"58","author":"Kalman","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1016\/j.jtct.2025.05.023_bib0019","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s12032-019-1245-5","article-title":"Splenic irradiation before allogeneic stem cell transplantation for myelofibrosis","volume":"36","author":"Helbig","year":"2019","journal-title":"Med Oncol"},{"issue":"4","key":"10.1016\/j.jtct.2025.05.023_bib0020","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/s41409-023-01913-9","article-title":"Splenic irradiation prior to allogeneic hematopoietic cell transplantation for patients with myelofibrosis","volume":"58","author":"Bales","year":"2023","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.jtct.2025.05.023_bib0021","article-title":"Pretransplant splenic irradiation in patients with myeloproliferative neoplasms","volume":"7","author":"Ponce","year":"2022","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.jtct.2025.05.023_bib0022","doi-asserted-by":"crossref","DOI":"10.1038\/s41409-024-02291-6","article-title":"Anti-T-lymphocyte globulin improves GvHD-free and relapse-free survival in myelofibrosis after matched related or unrelated donor transplantation","author":"Rathje","year":"2024","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"10.1016\/j.jtct.2025.05.023_bib0023","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","article-title":"A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)","volume":"115","author":"Passamonti","year":"2010","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.jtct.2025.05.023_bib0024","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1182\/blood-2018-12-890889","article-title":"Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation","volume":"133","author":"Gagelmann","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2025.05.023_bib0025","article-title":"Clinical and immune effects of peri-transplantation JAK inhibition for myelofibrosis","author":"Rathje","year":"2024","journal-title":"Am J Hematol"},{"issue":"9","key":"10.1016\/j.jtct.2025.05.023_bib0026","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/leu.2013.119","article-title":"Mutations and prognosis in primary myelofibrosis","volume":"27","author":"Vannucchi","year":"2013","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.jtct.2025.05.023_bib0027","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1200\/JCO.2017.76.4886","article-title":"MIPSS70: mutation-enhanced international prognostic score system for transplantation-age patients with primary myelofibrosis","volume":"36","author":"Guglielmelli","year":"2018","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jtct.2025.05.023_bib0028","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1056\/NEJMoa2408941","article-title":"Clearance of driver mutations after transplantation for myelofibrosis","volume":"392","author":"Gagelmann","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2025.05.023_bib0029","article-title":"Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the EBMT, ASTCT, CIBMTR, and APBMT","author":"Sureda","year":"2024","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jtct.2025.05.023_bib0030","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","article-title":"International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the mount sinai acute GVHD international consortium","volume":"22","author":"Harris","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.jtct.2025.05.023_bib0031","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/s41409-024-02251-0","article-title":"Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the EBMT, ASTCT, CIBMTR, and APBMT","volume":"59","author":"Sureda","year":"2024","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jtct.2025.05.023_bib0032","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.bbmt.2009.10.025","article-title":"Outcome of transplantation for myelofibrosis","volume":"16","author":"Ballen","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1016\/j.jtct.2025.05.023_bib0033","doi-asserted-by":"crossref","first-page":"916","DOI":"10.3324\/haematol.2013.094284","volume":"99","author":"Lussana","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2025.05.023_bib0034","article-title":"Early liver complications after allogeneic haematopoietic stem cell transplantation in patients with myelofibrosis: a study on behalf of the Chronic Malignancies Working Party of the EBMT","author":"Robin","year":"2023","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.jtct.2025.05.023_bib0035","doi-asserted-by":"crossref","first-page":"3551","DOI":"10.1038\/s41375-021-01276-4","article-title":"Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT","volume":"35","author":"Kroger","year":"2021","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.jtct.2025.05.023_bib0036","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1002\/ajh.27292","article-title":"JAK inhibitor treatment-resistant splenomegaly before transplantation in myelofibrosis: splenectomy or radiotherapy?","volume":"99","author":"Finazzi","year":"2024","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.jtct.2025.05.023_bib0037","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/j.1365-2141.2010.08527.x","article-title":"Splenectomy produces a rapid but transient decrease of the frequency of circulating CD34+ haematopoietic progenitor cells in primary myelofibrosis","volume":"152","author":"Massa","year":"2011","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.jtct.2025.05.023_bib0038","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.bbmt.2017.03.002","article-title":"The impact of splenectomy in myelofibrosis patients before allogeneic hematopoietic stem cell transplantation","volume":"23","author":"Robin","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jtct.2025.05.023_bib0039","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/ajh.26034","article-title":"Splenectomy before allogeneic hematopoietic cell transplantation for myelofibrosis: a French nationwide study","volume":"96","author":"Bossard","year":"2021","journal-title":"Am J Hematol"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725012072?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725012072?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T22:02:36Z","timestamp":1762639356000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636725012072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":39,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S2666636725012072"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2025.05.023","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pilot Study of Low-Dose Splenic Irradiation and Transplantation in JAK Inhibitor-Refractory Myelofibrosis With Splenomegaly","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2025.05.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of The American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}